Unaudited Financial Results For The Quarter Ended December 31, 2017.
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter and nine months ended December 31, 2017, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 12:30 p.m. and concluded at 2:00 p.m.... Board Meeting For The Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2017 And Intimation Of Closure Of Trading Window.
This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, January 24, 2018, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017. Please be informed that the Trading Window for trading in the Equity shares of the Company will be closed from January 16, 2018 to January 26, 2018, both days inclusive.... Shareholding for the Period Ended December 31, 2017
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here Statement Of Investor Complaints For The Quarter Ended December 31, 2017
In compliance with Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith a statement for the quarter ended December 31, 2017,giving number of investor complaints pending at the beginning of the quarter, those received during the quarter, disposed of during the quarter and those remaining unresolved if any, at the end of the quarter. Request you to take the same on record. This $17 billion dilemma will make or break Reckitt's CEO Rakesh Kapoor: Gadfly
Pfizer isn't the only route to solving Reckett's growth problem. Some are less obvious, but that's not an issue for Kapoor as he has a habit of doing the unexpected. Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Listing Regulations, please find below details of the meeting scheduled with an Analyst/Institutional Investor: Day and Date : Friday, December 8, 2017 Name of the Analyst/Institutional Investor : SBI Mutual Fund and its Fund Managers Meeting type : One on one Meeting Location: Mumbai... US FDA approves Pfizer's Sutent to treat adult patients at high risk of recurrent RCC
Pfizer has announced that the US Food and Drug Administration has approved a new indication expanding the use of Sutent (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent Pfizer appoints Albert Bourla as chief operating officer
Pfizer has announced that Albert Bourla has been named chief operating officer effective January 1, 2018
Golden Cross Screener: Pfizer gains today despite overall fall in markets
Pfizer is one of the stocks to break into the Golden Cross Screener today (where the 50 day average share price crossed above the stock's 200 day average). The company had reported its Q2 results a few days ago, announcing a 12% dip in standalone net profit YoY to Rs111.15 crore for the quarter ending 30 September 2017. The stock is currently abuzz on news that the company may have the first patented vaccine - for pneumonia - the Indian government will buy. Pfizer has exclusivity to sell the vaccine until 2026. To see the full screener click here.
Pfizer Q2 net dips 12% at Rs111.15 crore
Pfizer's standalone revenue from operations rose to Rs571.11 crore as against Rs557.66 crore for the same period year ago